




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
Glomerulardisease,NephroticSyndromeOverviewDefinitionofglomerulardiseaseDefinitionnephroticsyndromePathologyofprimarynephroticsyndromeandclinicalfeaturesDiagnosisandDifferentialdiagnosisComplicationsTreatmentofprimarynephroticsyndromeSecondarynephroticsyndrome-Diabeticnephropathy-Lupusnephritis-RenalAmyloidosis-HBV-associatednephropathy
GlomerularDiseaseAheterogeneousgroupofdisease,manifestatingwithhematuria,proteinuria,edemaandhyperension,etcPrimaryglomerulardiseaseSecondaryglomerulardiseaseGeneticglomerulardiseaseDividedbyetiology:ThemostcommonsyndromeofkidneydiseaseAcuteNephriticsyndromeNephroticsyndromeAsymptomaticurinaryabnormalitiesAcuterenalfailureorRapidlyprogressiverenalfailureChronickidneydisease(Table1)
(一)急性腎炎綜合征(二)腎病綜合征(三)無癥狀性尿檢異常(四)急性及急進(jìn)性腎衰竭綜合征(五)慢性腎臟病(表1)2012KDIGO指南更新再強(qiáng)調(diào):
蛋白尿水平及GFR是評(píng)估CKD進(jìn)展的重要指標(biāo)圖注:綠色:低風(fēng)險(xiǎn)(如沒有其他腎臟疾病的標(biāo)志物);黃色:中度增加風(fēng)險(xiǎn);桔色:高風(fēng)險(xiǎn);紅色:非常高風(fēng)險(xiǎn)持續(xù)性蛋白尿診斷標(biāo)準(zhǔn)和范圍Kidneyinter.,Suppl.2012;2:337–414.
Pathophysiology:ProteinuriaFigure3.ThreemainmechanismofproteinuriaGlomerular(increasefiltration)Tubular(decreasereabsorption)Overflow(markedoverproduction ofaparticularproteinNephroticSyndromeItisnotadiseasebutagroupofsignsandsymptomspresentswithedemaproteinuriausually>3.5g/24hrsserumalbumin<30g/Lotherfeatures:hyperlipidaemia,andhypercoaguablestatePathophysiologyPRIMARYNEPHROTICSYNDROMEMinimalChangeDiseaseMesanginalProliferativeGlomerulonephritisFocalSegmentalGlomerulosclerosisMembranousNephropathyMembranoproliferativeGlomerulonephritis(MPGN)NormalglomerulusLightmicrographofanormalglomerulus.Thereareonly1or2cellspercapillarytuft,thecapillarylumensareopen,thethicknessoftheglomerularcapillarywall(longarrow)issimilartothatofthetubularbasementmembranes(shortarrow),andthemesangialcellsandmesangialmatrixarelocatedinthecentralorstalkregionsofthetuft(arrows).CourtesyofHelmutGRennke.
Lightmicrographofanessentiallynormalglomerulusinminimalchangedisease.Thereareonly1or2cellspercapillarytuft,thecapillarylumensareopen,thethicknessoftheglomerularcapillarywallsisnormal,andthereisneitherexpansionnorhypercellularityinthemesangialareasinthecentralorstalkregionsofthetuft(arrows).CourtesyofHelmutGRennke.
MinimalchangediseaseMinimalchangediseaseMinimalchangediseaseElectronmicrographofanormalglomerularcapillaryloopshowingthefenestratedendothelialcell(Endo),theglomerularbasementmembrane(GBM),andtheepithelialcellswithitsinterdigitatingfootprocesses(arrow).TheGBMisthinandnoelectrondensedepositsarepresent.Twonormalplateletsareseeninthecapillarylumen.CourtesyofHelmutRennke,MD.
NormalglomerulusElectronmicrographinminimalchangediseaseshowinganormalglomerularbasementmembrane(GBM),noimmunedeposits,andthecharacteristicwidespreadfusionoftheepithelialcellfootprocesses(arrows).CourtesyofHelmutRennke,MD.
MinimalchangediseaseMinimalChangeDiseaseMostfrequentcauseofnephroticsyndromeinchildren.generalizededemawithnormalrenalfunctionandselectiveproteinuria.Hematuriaisabsentandpatientsarenormotensive.LM-Normal.IF-Negative.EM-footprocessfusion.Respondsreadilytosteroids,althoughrelapsesarecommon.Thelongtermprognosisisexcellent.SteroidresistantpatientsmayprogresstoFSGS.
MembranousnephropathyMostcommoncauseinadults.Especiallyelderlypeople.LM:glomerularbasementmembranethickeningwithnocellularproliferation.IF:granulardepositsofIgGandC3alongthebasementmembrane.EM:thickeningofbasementmembraneandfootprocessfusion.Theprognosisisvariable.Spontaneousremissionsoccurinsomecaseswhereasothersprogressslowlytochronicrenalfailure.Steroidsandimmunesuppressiveagentsmaybeeffectiveinretardingtheprogressiontorenalfailure.
ImmunofluorescencemicroscopyofMN(IgG)MembranousnephropathyLightmicrographofmembranousnephropathy,showingdiffusethickeningoftheglomerularbasementmembrane(longarrows)withessentiallynormalcellularity.Notehowthethicknessoftheglomerularcapillarywallsismuchgreaterthanthatoftheadjacenttubularbasementmembranes(shortarrow).Therearealsoareasofmesangialexpansion(asterisks).Immunofluorescencemicroscopy(showinggranularIgGdeposition)andelectronmicroscopy(showingsubepithelialdeposits)aregenerallyrequiredtoconfirmthediagnosis.CourtesyofHelmutRennke,MD.
ComplicationsInfectionCoagulationdisordersAcuterenalfailureProteinmalnutritionanddyslipidemiaTheimpairmentofnormaldefenseisnotwellunderstood;
LowlevelsofimmunoglobulinGInfectionPatientswiththenephroticsyndromearesusceptibletoinfection,whichwastheleadingcauseofdeathinchildrenwiththenephroticsyndromebeforeantibioticsbecameavailable.Pneumonia,peritonitiswereparticularlycommonComplicationsdecreasedlevelsofantithrombin
,plasminogen(urinarylosses),
hyperfibrinogenemiaincreasedplateletactivation
10to40percentofpatientsdevelopvenousthromboemboli,particularlydeepveinandrenalveinthrombosis
Renalveinthrombosiscanpresentacutelyor,muchmorecommonly,inanindolentmanner.
Theacutepresentationincludesflankpain,grosshematuria,andadeclineinrenalfunction..
Thromboembolism
Hypercoagulability
Hypovolemia
InterstitialedemaRenalperfusion↓ObstructionoftubularlumenRenalveinthrombosisNonsteroidalantiinflammatorydrugsAndotherdrugsPre-renalRenalfailureAcuteRenalFailurehypoalbuminemia,MalnutritionRetardationnegativenitrogenbalancehyperlipidemiaUrinarylossofhormones:vitamineD,T3andT4Edemaofthegastrointestinaltract:anorexiaandvomitInfectionImmunoglobin↓↓ThrombosisandemboliCardiovasculardiseaseeventsacceleratedatherosclerosisProteinmalnutrition
AmyloidosisLupusnephritisDiabeticnephropathyNephroticsyndromeassociatedmalignanceDifferentialDiagnosisRestDietary:sodiumandwaterrestriction(approximately3g/day)DiureticsLowerintraglomerularpressureStatintherapydonotrecommendroutineprophylacticanticoagulation.Generaltherapy(Nonimmunosuppressivetherapies
)TreatmentImmunosuppressivetherapyTreatmentGlucocorticoidsOtherimmunosuppressiveagents
—
Cyclophosphamide
orcyclosporineA
aloneorincombinationwithprednisonforrelapsing,glucocorticoid-dependentdiseaseorglucocorticoid-resistdisease.Dailyoralprednisone
(1mg/kgperdaytoamaximumof80mg/day)Asingledoseuponawakening(usuallybetweesevenandnineAM)Someclinicianspreferalternate-dayprednisonefromthebeginningtominimizethetoxicityoflong-termdailyprednisone,ataninitialdoseof2mg/kgeveryotherday(toamaximumdoseof120mg)Minimumofeightweeks,maximumduration
is16weeksSlowtaperingisperformedbothtosustaintheremissionandtoavoidadrenalsuppressionGlucocorticoidtherapyResponsetoGlucocorticoidtherapy
Acompleteremissionisareductioninproteinuriato300mg/day.Apartialresponseisareductioninproteinuriaof50percent,withabsolutevaluesbetween300mgand3.5g/day.Arelapseisreturnofproteinuriatoapproximately3.5gm/dayinpatientswhohadpreviouslyundergoneacompleteorpartialremission.Glucocorticoid-dependencereferstorelapsewhilerequirementforcontinuationofsteroidstomaintainremissionGlucocorticoid-resistancereferstolittleornoreductioninproteinuriaafter16weeksofadequateprednisone
therapy.Infectiousdisease:HeightenedriskoftypicalinfectionsOpportunisticinfections:HerpeszosterEndocrine:DiabetesmellitusBone:Osteoporosis
Gastrointestinal:Pepticulcerdisease,Pancreatitis,UGBEye:Elevatedintraocularpressure/glaucoma,ExophthalmosCardiovascular:HypertensionDermatologicandsofttissue:Skinthinningandpurpura,Cushingappearance,Acne.Majorsideeffectsassociatedwithcorticosteroidtherapy
Cyclophosphamide(CTX)
Azathioprine
(AZA)
Cyclosporine
(CysA)
Mycophenolate(MMF)
Tacrolimus(FK506)ImmunosuppressiveagentsNotthefirstchoiseanddon’tusealoneFrequentlyrelapsing,glucocorticoid-dependentorglucocorticoid-resistcasesImmunosuppressiveagentsA12-weekcourseof2mg/kgperdayofcyclophosphamide
Cumulativedoseof168mg/kgNeutropeniaandinfection—BonemarrowsuppressionGonadaltoxicity—atotaldosegreaterthan200to300mg/kgforCTX,Malignancy—acutelymphoblasticleukemia.AlopeciaandhemorrhagiccystitisLiverfunctioninjury.Otherscyclophosphamide-mostcommonlyuse
AlkylatingagentsCyclosporineatadoseof3to5mg/kgperdaytomaintainwholebloodtroughlevelsof100to200μg/LatleastsixmonthsCyclosporinesolutioncanbemixedwithmilk,chocolatemilk,ororangejuice(butnotgrapefruitjuice)atroomtemperature.Tacrolimusis0.05mg/kgperdaytomaintainwholebloodtroughlevelsbetween3and5μg/L.Thedosemaybeincreasedtoachieveahighertroughlevelbetween5and8μg/L,ifthereisnoreductioninproteinuriabytwomonths,providingtherenalfunctionhasnotworsened.
DOSAGEANDADMINISTRATIONCalcineurininhibitorsNephrotoxicity
—Neurotoxicity—
severeheadache,visualabnormalities,andseizuresMetabolicabnormalities
—
GlucoseintoleranceInfections
—
Bacterial,viralandfungalinfectionsRiskofmalignancy
Othersideeffects
—
Gastrointestinalsideeffectsincludeanorexia,nausea,vomiting,diarrheaandabdominaldiscomfort
AdverseeffectassociatewithCalcineurininhibitorsThetargetdosageofMMFisgenerallybetween1.5to2gramsdaily.Startingwithlowerdosesatfirst(eg,500mgdailyforseveraldays)mayimprovepatients'gastrointestinaltoleranceofMMFAdverseeffect:Bonemarrowsuppression:cytopenias,requireregularmonitoringGastrointestinal
—
nearly75percentinitiallyhadgastrointestinal(GI)symptoms,includingnausea,diarrhea,andabdominalcramping.ThesesymptomsweretoleratedbetterwithtimeMycophenolatemofetil:
(MMF)
Treatedwithheparin
followedbywarfarinThegoalINRis1.5to2.0Durationofanticoagulation
—
Warfarin
therapyisgivenforaminimumof6to12months.Aslongasthepatientremainsnephrotic.Serumalbuminbelow2.0g/dL(20g/L)OptimaltherapyofhypercoagulabilityLotension,Losartan,Vasartan
,etclowerintraglomerularpressure,reductioninproteinexcretion,slowtherateofdiseaseprogression.Itisnotdependanttotheantihypertensiveeffect.Itispositivelyrelatedtothedoseofdrug.ACEI
and
ARBAcuterenalfailureHyperkalemiaNotices:Hypovolummia,useNSAIDtogetherSideeffectsPathologyIncidenceInfectionHematuriaHypertensionRenalinjuryTreatmentPrognosisMCDchildren(75%)commonlyseen---90%steroidsgoodFSGS5-15%younger+(65%)+(30%)+(10%)1/3
sensitive,dependentandresistrespectively
about10yearstoESRDMsPGN30%youngerandadult+++normalsomesensitive,somenotaccordingpathologyMembranousGNelderlyrarerareSteroid+cytotoxic1/4spontaneousremissions,progressslowlyMPGNyounger+grosshematuria+++(25%)resistpoorClinicalFeaturesandPathologyofPrimaryNephroticSyndrome20percentofcasesofsteroid-resistantNSareduetomutationsoftheNPHS1,NPHS2,WT1gene.Inpatientswithsteroid-resistantNSduetogenemutation,
wedonotrecommendimmunosuppressivetherapyOptimaltreatmentofSRNSnotduetoageneticdisorderis
unknown,Acombinationofcyclosporine
andprednisoneisrecommended,.Alternatively,cyclophosphamide,andtacrolimus
havealsobeenused.Hotpoints1:AboutFSGSSecondaryGlomerularDisease–-SecondarynephroticsyndromeWhytalkaboutdiabeticnephropathy?MostcommonsinglecauseESRDintheUS,Europe,andJapan17milliondiabeticsintheUS20-30%diabetics(bothtypeIandtypeII)developdiabeticnephropathy40%ESRDinUSrelatedtodiabeticnephropathyDefinitionAmicrovascularcomplicationofdiabetesmarkedbyalbuminuria,elevatedbloodpressure,andadeterioratingcoursefromnormalrenalfunctiontoESRD.ClinicalfeaturesGraduallyprogressiveproteinuriaMicroalbuminuriaisfirstclueBlandurinesediment–noRBCs,casts,etcGraduallydecreasingGFRPatientsasymptomatic,butdevelopworseninghypertensionNature
courseHowtodistinguishfromanotherkidneydiseaseLikelydiabetes:MacroalbuminuriaMicroalbuminuria,andPresenceofdiabeticretinopathyType1diabetesforatleast10yearsNoactiveurinarysedimentLikelyanothercauseofCKD:AbsenceofretinopathyRapidlydecreasingGFRhematuriaRefractoryhypertensionSignsorsxofothersystemicdiseaseTreatmentEarlyscreening TightglycemiccontrolHTNmanagementUseACEIasfirstline,ifnottolerated,useARB.UsethemaximumdoseastoleratedLupusnephritisSystemiclupuserythematosus(SLE)isamultisystem,autoimmuneds.withantibodiesdirectedagainstawidevarietyofcellularcomponentsLupusnephritisisoneofthemostseriousmanifestationsof(SLE).Frequency,race,sexandage
TheprevalenceofSLEis1caseper2000inthegeneralpopulation.SLEismorecommoninblackpeople,HispanicpeopleandAsianthaninwhitepeople.lupusnephritismorecommoninfemalesandtypicallyoccursinpatientsaged20-40years;clinicalrenaldiseasewithaworseprognosisismorecommoninmaleswithSLE.
ClinicalfeaturesVariousorgansystemsareeffected,likeskin,joints,serousmembranes,heart,neurologic,bloodandthekidneys.Rash,oralornasalulcers,synovitis,fatigue,fever,arthritis,serositis,edema,etc.ClinicalsignsLaboratoryStudiesTestsofSLEdiseaseactivityDiseaseactivity:ANA,anti-dsDNA,C3,C4,andCH50
,ESRorCRP.Creatine,urea,urialysisRenalbiopsyisusefulindeterminingprognosisandtreatment.IF:Fullhouse.LupusNephritisStageFeaturesStageINormallookingglomeruliStageIIMesangialexpansionStageIIIFocalproliferative<50%StageIVDiffuseProlif.>50%stageVMembranousStageVIAdv.sclerosinglesionsPathologyoflupusnephritisAmyloidosisAmyloidosisisaclinicaldisordercausedbyextracellulardepositionofinsolubleabnormalfibrilsthatinjuretissue.AmyloidosisALamyloid(primaryamyloid)associatedwithplasmacelldisorders,mostlyovertmyelomaAAamyloid(secondaryamyloid)isanacutephasereactantassociatedwithchronicinflammatorydiseasesliketuberculosis,osteomyelitis,rheumatoidarthritisandbronchiectasisMorecommoninelderlyTheamyloidisaneosinophilicextracellularsubstance,Congoredstainpositiveandblue-greenbirefringence.AmyloidosisArangeofclinicalpresentationswithrenal,heart,gastrointestine,localdepositionandotherproblemsRenalfailureandnephroticrangeproteinuriaarethemostcommonrenalpresentationAbnormalelevatingofMonoclonalIginbloodandlightchains(BenceJones)inurineinALamyloid.Relatedrenaldisordersincludelightchaindepositdisease,fibrillaryGNandimmunotactoidGNPrognosisforispoor.MonoclonalpatternSPEPUrinarymonoclonalproteinPanelB:Adense,localizedband(redasterisk)representingamonoclonalproteinofgammamobilityisseenonserumproteinelectrophoresisonagarosegel(anodeonleft).PanelA:Densitometertracingofthesefindingsrevealsatall,narrow-basedpeak(redasterisk)ofgammamobilityandareductioninthenormalpolyclonalgammaband.Themonoclonalbandhasadensitometricappearancesimilartothatofalbumin(alb),andhasbeenlikenedtoachurchspire.PanelB:Thisfigureillustratesthecelluloseacetateelectrophoreticpatternofaurinesample.Itrevealsadensebandofproteinwithbetamobility.PanelA:Densitometertracingshowsatall,narrow-basedpeakofbetamobility.Thesefindingsareconsistentwithaurinemonoclonalprotein(BenceJonesprotein);NormalpatternofSPEPCLINICALMANIFESTATIONSRenaldisease
—
asymptomaticproteinuriaorclinicallyapparentnephroticsyndromeCardiomyopathy
—
systolicordiastolicdysfunctionandheartfailure.syncopeduetoarrhythmiaheartblock,andanginaorinfarctionduetoaccumulationofamyloidinthecoronaryarteries.Gastrointestinaldisease
—
Hepatomegalywithorwithoutsplenomegaly.Bleeding,gastroparesis,constipation,etc.Neurologicabnormalities
—
Mixedsensoryandmotorperipheralneuropathyand/orautonomicneuropathyMusculoskeletaldisease
—pseudohypertrophy,alargetongueHematologicabnormalities
—bleedingdiathesis,factorXdeficiencySkinmanifestations
—waxythickening,easybruising,andsubcutaneousnodulesorplaques.Purpura,inaperiorbitaldistribution(raccooneyes).Others:Pulmonary,visualabilityOutcomeSurvivalfromonsetofsymptomsvariesfrom1moto10yr.Therateofdiseaseprogressionisvariableanddependsontheextentoforganinvolvement.HBV-associatednephropathyInfectionwithhepatitisBvirus(HBV)maybedirectlyassociatedwithavarietyofrenaldiseases,includ
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 四年級(jí)數(shù)學(xué)(三位數(shù)乘兩位數(shù))計(jì)算題專項(xiàng)練習(xí)及答案
- Unit 6 I'm going to study computer science. Section B 2a~2e Reading教學(xué)設(shè)計(jì)-2024-2025學(xué)年人教新目標(biāo)八年級(jí)英語上冊(cè)
- 11條saf技術(shù)路線總結(jié)
- 合同范例雨天順延
- 三年級(jí)道德與法治下冊(cè) 第一單元 珍愛生命 2學(xué)會(huì)自救自護(hù)教學(xué)實(shí)錄 蘇教版
- 代工包裝合同范例
- 吊裝垃圾清運(yùn)輸合同范本
- 廁所革命合同范例
- 鄉(xiāng)村改建施工合同范例
- 前臺(tái)收銀員年終總結(jié)例文
- 靜物速寫課件
- 機(jī)電系統(tǒng)調(diào)試方案
- 腫瘤與睡眠障礙-分析腫瘤與睡眠障礙之間的聯(lián)系及改善睡眠的方法
- 實(shí)驗(yàn)室感染性物質(zhì)運(yùn)輸
- 部編人教版五年級(jí)下冊(cè)道德與法治簡答題歸納總結(jié)
- 2022年大唐集團(tuán)招聘筆試試題及答案
- 醫(yī)療器械經(jīng)營質(zhì)量管理規(guī)范培訓(xùn)試題及答案
- 監(jiān)理工作業(yè)務(wù)指導(dǎo)手冊(cè)(頁含圖表)
- 新大象版科學(xué)四年級(jí)下冊(cè)珍貴的淡水資源課件公開課一等獎(jiǎng)?wù)n件省賽課獲獎(jiǎng)?wù)n件
- 2023年陜西延長石油(集團(tuán))有限責(zé)任公司招聘筆試題庫含答案解析
- 水稻種子生產(chǎn)技術(shù)
評(píng)論
0/150
提交評(píng)論